Liposomes Patents (Class 424/450)
  • Stabilizing camptothecin pharmaceutical compositions
    Patent number: 10456360
    Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.
    Type: Grant
    Filed: October 15, 2016
    Date of Patent: October 29, 2019
    Assignee: Ipsen Biopharm Ltd.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
  • Lipids for therapeutic agent delivery formulations
    Patent number: 10441659
    Abstract: The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: October 15, 2019
    Assignee: Nitto Denko Corporation
    Inventors: Joseph E. Payne, John A. Gaudette, Zheng Hou, Mohammad Ahmadian, Lei Yu, Victor Knopov, Violetta Akopian, Priya Karmali, Richard P. Witte, Neda Safarzadeh, Wenbin Ying, Jun Zhang
  • Method of assessing hair colour changes
    Patent number: 10444157
    Abstract: The invention provides a method of assessing the potential color protecting effect in vivo of a test formulation such as rinse-off hair treatment formulation, the method comprising the steps of: providing a sample of the test formulation to be assessed; providing a model substrate in the form of a hair switch which has been artificially colored; applying the test formulation to the hair switch; subsequently rinsing the test formulation from the hair switch; collecting the rinse liquor and analysing it for the presence of eluted color; characterized in that the artificial color used to color the hair switch is a permanent hair colorant with a shade level 1 or 2 according to the International Color Chart (I.C.C.). The method provides improved sensitivity and differentiation, and enables the tester to compare different technologies in terms of effectiveness.
    Type: Grant
    Filed: September 1, 2014
    Date of Patent: October 15, 2019
    Assignee: CONOPCO, INC.
    Inventors: Claire Louise Richards, Neil Scott Shaw
  • Cavitation-inducing polymeric nanoparticles
    Patent number: 10441529
    Abstract: The invention disclosed herein relates to a nanoparticle comprising: a cup having a cavity, and a gas pocket present in the cavity, wherein the gas pocket is partially encapsulated by the cup. Typical uses of the nanocups include initiating inertial cavitation during simultaneous exposure to ultrasound, and/or as drug carriers to achieve targeted drug delivery in response to ultrasound excitation.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: October 15, 2019
    Assignee: Oxsonics Limited
    Inventors: James Kwan, Rachel Myers, Constantin-Cassios Coussios, Apurva Shah
  • Oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and application thereof
    Patent number: 10441600
    Abstract: The present invention provides an oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and an application thereof. The core sequences of the oligodeoxy nucleotide is TTTCSCGCS, wherein S is C or G. The oligodeoxy nucleotide above further comprises an antisense strand and a modified type thereof. The oligodeoxy nucleotide according to the present invention plays a role of inhibiting the tumor growth in vitro and vivo, and is expected to be used for preparing drugs for inhibiting tumor growth, with high specificity and high inhibition ratio.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: October 15, 2019
    Assignees: JIANGSU KEYGEN BIOTECH CORP., LTD, NANJING NEW INDUSTRY INVESTMENT GROUP CO., LTD
    Inventors: Xuegen Wang, Qing Ye, Yijun Sun
  • FKBP52 specific androgen receptor inhibitor, MJC13, for use in treating breast cancer
    Patent number: 10434075
    Abstract: Embodiments of the current invention include methods and compositions for treating breast cancer by administering an effective amount of MJC13 to a subject in need thereof.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: October 8, 2019
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Marc B. Cox, Jennifer Richer
  • Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
    Patent number: 10434064
    Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: October 8, 2019
    Assignee: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
  • Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose
    Patent number: 10434088
    Abstract: Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: October 8, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • Microfluidic liposome synthesis, purification and active drug loading
    Patent number: 10434065
    Abstract: Microfluidic methods and systems are provided for continuous flow synthesis and active loading of liposomes, which include a liposome formation region configured to form a population of liposomes and a microdialysis region downstream from the liposome formation region and configured to form a transmembrane gradient for active drug loading of the liposomes. Microfluidic methods and systems for high throughput production of liposomes are also provided featuring high aspect ratio microchannels.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: October 8, 2019
    Assignee: University of Maryland, College Park
    Inventors: Renee Hood, Donald Lad DeVoe
  • Liposome composition
    Patent number: 10426715
    Abstract: The object is to develop a liposome composition showing superior persistency of moisturizing effect and superior persistency of skin firmness and tightness-imparting effect, as well as superior temporal stability of liposomes. There is provided a liposome composition containing the following ingredients (a) to (e): (a) a phospholipid, (b) a Tremella fuciformis extract, (c) vitamin E or a derivative thereof, (d) a polyhydric alcohol having an IOB value of 1.5 to 5, and (e) water.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: October 1, 2019
    Assignee: KOSE CORPORATION
    Inventor: Mitsuru Yoshida
  • Encapsulated diagnostics and therapeutics in nanoparticles—conjugated to tropic cells and methods for their use
    Patent number: 10426801
    Abstract: A therapeutic or diagnostic delivery vehicle is provided. The delivery vehicle may include one or more particles, such as microparticles, nanoparticles and stimuli-responsive particles, conjugated to a tropic cell that targets at least one pathological entity or site. In addition, a pharmaceutical composition is provided. The pharmaceutical composition may include, among other things, a particle conjugated to a tropic cell such as those discussed above and at least one diagnostic or therapeutic agent, such as those described herein. In some aspects, the tropic cell may target at least one pathological entity or site. Further, methods for diagnosing, monitoring or treating a pathological condition in a subject are provided. Such methods may include administering a therapeutically effective amount of the pharmaceutical composition to a subject.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: October 1, 2019
    Assignee: City of Hope
    Inventors: Karen Aboody, Alexander Annala, Rachael Mooney, Jacob Berlin, Yiming Weng
  • Anti-MFI2 antibodies and methods of use
    Patent number: 10428156
    Abstract: Provided are novel anti-MFI2 antibodies and antibody drug conjugates, and methods of using such anti-MFI2 antibodies and antibody drug conjugates to treat cancer.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: October 1, 2019
    Assignee: Abbvie Stemcentrx LLC
    Inventors: Samuel Williams, Laura Saunders, Holger Karsunky, Mandy Boontanrart
  • Nanostructures for modulating intercellular communication and uses thereof
    Patent number: 10413565
    Abstract: Nanostructures, compositions and methods for treating vesicle-related or exosome-related conditions are provided. In some cases, the nanostructures and/or compositions may be used to treat cancers, neurological disorders, rheumatologic disorders, viral disorders or other diseases or conditions at least in part by regulating vesicle uptake. Methods of analyzing, imaging and modulating vesicles and cellular vesicles processes are also provided.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: September 17, 2019
    Assignee: Northwestern University
    Inventors: Michael P. Plebanek, C. Shad Thaxton, Raja Kannan Mutharasan, Nicholas L. Angeloni, Kaylin M. McMahon
  • Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration
    Patent number: 10406088
    Abstract: Provided is a topical formulation comprising (1) three or more of the following four components a through d, or (2) component c and one or more of components a, b or d: (a) a skin barrier repair formulation comprising fatty acid, bilayer-stabilizing steroid, and complex lipid (CL), wherein the weight ratio of CL to steroid is from about 1.5:1 to about 8:1, and the weight ration of CL to FA is from about 4:1 to about 1:1, the lipids present in an amount from about 3% wt. to about 10% wt.; (b) a natural moisturizer formulation, wherein the natural moisturizers are urea, urocanic acid, pyrrolidone-5-carboxylic acid, lactic acid or free amino acid; (c) one or more retinoids in an amount from about 0.01% wt. to about 10% wt.; or (d) taurine in an amount from about 0.1% wt. to about 5% wt.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: September 10, 2019
    Assignee: TetraDerm Group LLC
    Inventors: Thomas Sköld, Georgia Levis, Michael J. Burns
  • Water soluble lipophilic materials
    Patent number: 10406117
    Abstract: The present invention is a water-soluble form of lipophilic molecules contained in liposomes. In one embodiment, the lipophilic molecule is crystalline lutein and the lutein-loaded liposomes are included in pharmaceutical products, medical devices, and dietary supplements industry, with potential for chewable tablets, fortification of beverages, effervescent tablets, uncoated tablets, nutritional bars, and functional foods in addition to cosmetic industry.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: September 10, 2019
    Assignee: KEMIN INDUSTRIES, INC.
    Inventor: Diogo de Sousa Martins
  • Polynucleotides encoding methylmalonyl-CoA mutase
    Patent number: 10406112
    Abstract: The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering an mRNA encoding an MCM polypeptide.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: September 10, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Paolo Martini, Vladimir Presnyak, Kerry Benenato
  • Compositions and methods to modify cells for therapeutic objectives
    Patent number: 10392446
    Abstract: The present disclosure provides compositions and methods that rapidly and selectively modify cells of the immune system to achieve therapeutic objectives. The methods can be practiced in vivo and any cell type that expresses a known marker can be targeted for a therapeutic objective.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: August 27, 2019
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventor: Matthias Stephan
  • Topical skin compositions for treating wrinkles
    Patent number: 10391049
    Abstract: Disclosed is a method of treating a fine line or wrinkle in a person's skin. The method includes topically applying to the fine line or wrinkle a composition comprising an effective amount of Commiphora mukul resin or an extract thereof that includes oleo gum resin. Topical application of the composition to the fine line or wrinkle reduces the appearance of the fine line or wrinkle.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 27, 2019
    Assignee: Mary Kay Inc.
    Inventors: Tiffany Florence, Michelle Hines, David Gan, Wanli Zhao
  • Compounds and compositions for intracellular delivery of therapeutic agents
    Patent number: 10392341
    Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: August 27, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Kerry E. Benenato, Mark Cornebise
  • Liposomal cisplatin compositions for cancer therapy
    Patent number: 10383823
    Abstract: The present invention provides a composition for the treatment of cancer including zwitterionic liposomes consisting essentially of: 50-65 mol % of a phosphatidylcholine lipid, 30-45 mol % of cholesterol, and 2-8 mol % of a PEG-lipid; and cisplatin. Cisplatin is encapsulated in the liposomes in an amount such that the ratio of the total lipid weight to the cisplatin weight is from about 65:1 to about 95:1. Methods for the preparation of liposomal cisplatin and the treatment of cancer are also disclosed.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: August 20, 2019
    Assignee: MALLINCKRODT LLC
    Inventor: William McGhee
  • AAV-mediated gene therapy for RPGR X-linked retinal degeneration
    Patent number: 10383922
    Abstract: Described herein are methods of preventing, arresting progression of or ameliorating vision loss and other conditions associated with retinitis pigmentosa and x-linked retinitis pigmentosa in a subject. The methods include administering to the subject an effective concentration of a composition comprising a recombinant adeno-associated virus (AAV) carrying a nucleic acid sequence encoding a normal retinitis pigmentosa GTPase regulator (RPGR gene), or fragment thereof, under the control of regulatory sequences which express the product of the gene in the photoreceptor cells of the subject, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: August 20, 2019
    Assignees: The Trustees of the University of Pennsylvania, University of Florida Research Foundation, Incorporated
    Inventors: William A Beltran, Gustavo D Aguirre, Samuel G Jacobson, Artur V Cideciyan, Alfred S Lewin, Sanford L Boye, William W Hauswirth, Wen-Tao Deng
  • Method of assessing hair colour changes
    Patent number: 10386306
    Abstract: The invention provides a method of assessing the potential color protecting effect in vivo of a test formulation such as rinse-off hair treatment formulation, the method comprising the steps of: providing a sample of the test formulation to be assessed; providing a model substrate in the form of a hair switch which has been artificially colored; applying the test formulation to the hair switch; subsequently rinsing the test formulation from the hair switch; collecting the rinse liquor and analysing it for the presence of eluted color; characterized in that the artificial color used to color the hair switch is a permanent hair colorant with a shade level 1 or 2 according to the International Color Chart (I.C.C.). The method provides improved sensitivity and differentiation, and enables the tester to compare different technologies in terms of effectiveness.
    Type: Grant
    Filed: September 1, 2014
    Date of Patent: August 20, 2019
    Assignee: CONOPCO, INC.
    Inventors: Claire Louise Richards, Neil Scott Shaw
  • Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
    Patent number: 10383822
    Abstract: An object of the present invention is to provide an oxaliplatin-encapsulating liposome aqueous dispersion that has excellent long-term storage stability. The present invention provides an aqueous dispersion of liposomes encapsulating oxaliplatin, the oxaliplatin-encapsulating liposome aqueous dispersion containing 2-morpholinoethanesulfonic acid in an external aqueous phase.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: August 20, 2019
    Assignees: TAIHO PHARMACEUTICAL CO., LTD., TOKUSHIMA UNIVERSITY
    Inventors: Yusuke Doi, Tatsuhiro Ishida
  • Cholestosome vesicles for incorporation of molecules into chylomicrons
    Patent number: 10369114
    Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 6, 2019
    Assignee: THERASYN SENSORS, INC.
    Inventors: Jerome J. Schentag, Mary P. McCourt, Lawrence Mielnicki, Julie Hughes
  • Methods and compositions for liposomal formulation of antigens and uses thereof
    Patent number: 10369229
    Abstract: The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s).
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: August 6, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, MOLECULAR EXPRESS, INC.
    Inventors: Gary Fujii, Francis C. Szoka, Douglas S. Watson
  • Compartmentalised screening by microfluidic control
    Patent number: 10371699
    Abstract: The invention describes a method for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, comprising the steps of: a) compartmentalizing the compounds into microcapsules together with the target, such that only a subset of the repertoire is represented in multiple copies in any one microcapsule; and b) identifying the compound which binds to or modulates the activity of the target; wherein at least one step is performed under microfluidic control. The invention enables the screening of large repertoires of molecules which can serve as leads for drug development.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: August 6, 2019
    Assignees: President and Fellows of Harvard College, United Kingdom Research and Innovation
    Inventors: Andrew David Griffiths, David A. Weitz, Darren Roy Link, Keunho Ahn, Jerome Bibette
  • All-in-one skin-brightening formulations
    Patent number: 10363207
    Abstract: Certain dermatological formulations for direct skin application that correct for hyperpigmentation effects are provided. Such formulations include a number of different compounds that work synergistically to effectuate multiple and varied pathways to pigment removal and/or brightening within the dermal layer. The ability to do so without the necessity for hydroquinone, and thus with a suitable composition that is safe for handling and utilization by pregnant and nursing women, is accorded through a combination of specific ingredients in limited proportional ranges, as well. Such ingredients include kojic acid, niacinamide, sodium hyaluraonate, tocopherol, and licorice extract in very narrow ranges proportionally within an aqueous serum. The method of manufacture and use thereof such formulations are encompassed within the invention as well.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: July 30, 2019
    Inventor: Purvisha Patel
  • Sinus anesthesia kit
    Patent number: 10357267
    Abstract: An apparatus and method for anesthetizing various portions of a patient's nasal sinuses. For example, a kit can be provided that includes a first agent configured to modulate a rate of absorption of a subsequently-applied topical agent by one or more nasal structures. The kit also includes a first applicator configured to apply the first agent to a first portion of the one or more nasal structures. The kit also includes a second agent configured to anesthetize the first portion of the one or more nasal structures subsequent to application of the first agent and a second applicator configured to apply the second agent to the second portion of the one or more nasal structures.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: July 23, 2019
    Assignee: ENT Solutions Group LLC
    Inventors: James H. Atkins, Jr., Lori Rollwitz, Raymond L. Weiss
  • Crosslinked polymer nano-assemblies and uses thereof
    Patent number: 10358531
    Abstract: The invention provides a novel system of nano-assemblies and related method for delivery of therapeutic, diagnostic or imaging agent to biological sites. The compositions and methods of the invention enable the syntheses of novel polymeric nano-assemblies (nanoparticles) under non-emulsion conditions with the incorporation of hydrophobic guest molecules. The versatilities and advantages of the polymer nanoparticles of the invention include: (i) the guest molecules (e.g.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: July 23, 2019
    Assignee: University of Massachusetts
    Inventor: Sankaran Thayumanavan
  • Substance-encapsulating vesicle and process for producing the same
    Patent number: 10357454
    Abstract: Provided is a method for easily and efficiently producing encapsulated substance vesicles wherein a substance is encapsulated in the cavity of vesicles obtained by polymer self-assembly. Empty vesicles that have membranes comprising a first polymer that is a block copolymer with uncharged hydrophilic segments and a first kind of charged segments and a second polymer with a second kind of charged segments that carry a charge that is the opposite of said first kind of charged segments as well as spaces that are enclosed by said membranes are mixed in an aqueous medium with the substance that is to be encapsulated in the spaces.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: July 23, 2019
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Kazunori Kataoka, Akihiro Kishimura, Yasutaka Anraku, Kanjiro Miyata, Sayan Chuanoi, Tomoya Suma, Makoto Oba
  • Compositions and methods for bile acid particles
    Patent number: 10350169
    Abstract: Therapeutic compositions are disclosed which contain a therapeutic agent and a bile acid or bile acid conjugate. The compositions can be absorbed via enterohepatic circulation. The compositions include a cationic moiety and an anionic polymer, which are coupled through electrostatic interactions. The therapeutic compositions can be used for the treatment of diseases or disorders.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: July 16, 2019
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: You Han Bae, Yong-Kyu Lee, Md Nurunnabi, Hee Sook Hwang, Dongsub Kwag
  • Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
    Patent number: 10349884
    Abstract: Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: July 16, 2019
    Assignee: Sighpath Pharma Inc.
    Inventors: Lawrence Helson, George M. Shopp, Annie Bouchard
  • Fecal oxygenation
    Patent number: 10342828
    Abstract: Provided are a device and method for oxygenating fecal matter in a patient. The device includes an interior material defining a plurality of oxygen packets including oxygen to be introduced into the patient's digestive tract. An outer coating applied to an exterior of the interior material protects the interior material from an environment of the patient's digestive tract when the device is consumed, and is dissolved by a substance within the patient's digestive tract to expose the interior material to the patient's digestive tract after a delay.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: July 9, 2019
    Inventor: Roderick M. Dayton
  • Modulators of the eIF2alpha pathway
    Patent number: 10343981
    Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2? phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: July 9, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Peter Walter, Carmela Sidrauski, Diego Acosta Alvear, Michelle R. Arkin, Christopher G. Wilson, Kean Hooi Ang, Brian R. Hearn, Punitha Vedantham, Adam R. Renslo, Mervyn Maze, Susana Vacas
  • System and method for increasing a target zone for electrical ablation
    Patent number: 10342600
    Abstract: System for increasing a target zone for electrical ablation includes a treatment control module executable by a processor. The control module directs a pulse generator to apply pre-conditioning pulses to subject tissue cells in a pre-conditioning zone to electroporation, the pre-conditioning zone being smaller than a target ablation zone. After the pre-conditioning pulses have been applied, the control module directs the pulse generator to apply treatment pulses to electrically ablate the tissue cells in the target ablation zone. The pre-conditioning pulses cause the pre-conditioning zone to have a much higher conductivity so that the zone acts as a larger electrode area when the treatment pulses are applied, which result in a much larger target ablation zone than otherwise possible.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: July 9, 2019
    Inventors: Peter Callas, Wesley Chung Joe
  • Diabetic nutritional composition
    Patent number: 10342845
    Abstract: The present invention provides nutritional compositions as powders, lozenges, tablets or liquids that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the human system, and specifically for those humans predisposed to, or suffering from, the diabetic human condition. It is believed that the key ingredients of the present invention work synergistically together to aid in the slowing, stopping, or reversing the symptoms and metabolic disorder characteristic of the human diabetic condition. These essential components are comprised of uniquely-selected minerals, phytonutrients and vitamin combinations.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: July 9, 2019
    Inventor: Houn Simon Hsia
  • Nanoparticle-based tumor-targeted drug delivery
    Patent number: 10335420
    Abstract: An aqueous tumor-targeting liposome nanoparticle composition comprises an aqueous dispersion of liposome nanoparticles. The nanoparticles preferably encapsulate an anti-cancer chemotherapeutic agent, which can be added to a pre-formed liposome composition or can be incorporated in the liposomes during the formation of the liposomes. The liposome nanoparticles comprise a legumain-targeting lipid admixed with one or more other micelle or vesicle-forming lipid materials in the form of nanoparticulate liposomes dispersed in an aqueous carrier. A preferred tumor-targeting liposome nanoparticle composition comprises a legumain-targeting lipid component and polyethylene glycol-conjugated lipid component. The legumain-targeting lipid component comprising a hydrophobic lipid portion covalently attached to a legumain-binding moiety.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: July 2, 2019
    Assignee: The Scripps Research Institute
    Inventors: Ralph A. Reisfeld, Rong Xiang, Yunping Luo, Debbie Liao, Ze Liu, Tingmei Chen, Si Chen, Dan Lu
  • Recombinant filaggrin polypeptides for cell importation
    Patent number: 10336797
    Abstract: Disclosed are recombinant polypeptides that include (a) a filaggrin amino acid sequence and (b) a cell importation signal sequence that includes a motif of two to fifteen amino acids, wherein the motif includes at least one arginine residue and at least one methionine residue. Also disclosed are nucleic acids encoding the recombinant polypeptides of the present invention, and compositions that include the recombinant polypeptides and nucleic acids of the present invention. Methods of treating or preventing a skin disease or skin disorder using the compositions of the present invention are also included, as well as kits that include a sealed containing that includes a recombinant polypeptide of the present invention.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: July 2, 2019
    Assignee: Research Development Foundation
    Inventors: J. Timothy Stout, Binoy Appukuttan, Trevor McFarland
  • Synthetic nanostructures including nucleic acids and/or other entities
    Patent number: 10328026
    Abstract: Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may be surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and/or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: June 25, 2019
    Assignee: Northwestern University
    Inventors: C. Shad Thaxton, Chad A. Mirkin, Kaylin M. McMahon, Sushant Tripathy, Raja Kannan Mutharasan, David M. Leander, Andrea Luthi
  • Pulsed introduction of low-dose RANKL as a therapy for atherosclerosis
    Patent number: 10328123
    Abstract: Systems and methods for inhibiting atherosclerosis using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) through introduction of a low-dose of a RANK agonist suck as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: June 25, 2019
    Assignee: Saint Louis University
    Inventors: Rajeev Aurora, Anna Smith, Angel Baldan
  • Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms
    Patent number: 10322096
    Abstract: This application relates to methods and compositions for the administration of disulfiram (DSF) and heavy metals zinc and copper for the treatment and prevention of medical conditions, such as cancer. DSF and copper as well as DSF and zinc form active complexes that have been shown to be effective in the treatment of cancers. However, as described herein, DSF is incompatible with either copper or zinc for simultaneous oral administration. Included herein are improved methods and oral dosage forms comprising DSF and copper and DSF and zinc in fixed dose combinations that are configured to temporally stagger release of either DSF and copper or DSF and zinc after ingestion.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: June 18, 2019
    Assignee: Cantex Pharmaceuticals, Inc.
    Inventor: Stephen Marcus
  • Endoxifen for local transdermal therapy to the breast
    Patent number: 10322095
    Abstract: Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (DCIS) using local transdermal therapy (LTT). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, N-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or ENX) for treating breast cancer. The topical formulation may be described as a transdermal formulation and the topical formulation may comprise, consist essentially of, or consist of endoxifen as an active ingredient.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: June 18, 2019
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Seema Ahsan Khan, Oukseub Lee
  • Nanoparticles, nanoparticle delivery methods, and systems of delivery
    Patent number: 10322089
    Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to nanoparticles, compositions including nanoparticles, methods of making nanoparticles, and the like. In particular, embodiments of the present disclosure include nanoparticles and compositions for the sustained release (e.g., release at a predetermined rate to maintain a certain concentration for a certain period of time) of an agent, such as a small interfering RNA (siRNA) from the nanoparticle.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: June 18, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Tatsiana Lobovkina, Gunilla B. Jacobson, Richard N. Zare, Evgenios Neofytou, Ramin E. Beygui, Marie Russo
  • Method for lymph drainage
    Patent number: 10314877
    Abstract: The present invention relates to a mixture of active ingredients consisting of Taraxacum officinalis, Fagopyrum esculentum, Ruscus aculeatus, Solidago virgaurea and Orthosiphon stamineus or extracts of said plants or from said plants and extracts thereof, a composition comprising such a mixture, and uses thereof.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: June 11, 2019
    Assignee: ABOCA S.P.A. SOCIETA' AGRICOLA
    Inventors: Valentino Mercati, Anna Maidecchi
  • Exercise performance enhancers
    Patent number: 10307435
    Abstract: Disclosed are compositions, articles, and method for enhancing exercise performance in a subject. The method involves contacting the oral cavity of the subject with a composition comprising a sweet and caloric food product for a period sufficient to cause a cephalic phase response in the subject.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 4, 2019
    Assignee: University of Georgia Research Foundation, Inc.
    Inventor: Jamie A. Cooper
  • Wound dressings for the controlled release of therapeutic agents
    Patent number: 10307505
    Abstract: A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid, the material comprising: a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by the protease enzyme wherein the activities of both the wound healing therapeutic agent and the inhibitor increased by contacting the wound dressing material with a would fluid containing the protease enzyme. For example, the enzyme may be a matrix metalloproteinase, the therapeutic agent may be a reactive oxygen scavenger, and the inhibitor may be a tissue inhibitor of metalloproteinase (TIMP).
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: June 4, 2019
    Assignee: KCI USA, INC.
    Inventors: Breda Mary Cullen, Sara Jayne Gregory
  • Cell-free tissued engineered vascular grafts
    Patent number: 10300082
    Abstract: A composition containing a macrophage inhibitor may be administered in an effective amount to prevent, inhibit or reduce restenosis, thrombus or aneurysm formation in implanted polymeric vascular grafts. The composition may be administered prior to vascular graft implantation, at the same time as vascular graft implantation, following vascular graft implantation, or any combination thereof. Examplary macrophage inhibitors include bisphosphonates, anti-folate drugs and antibodies, preferably in a controlled release or liposomal formulation.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: May 28, 2019
    Assignee: Yale University
    Inventors: Christopher K. Breuer, Tarek Fahmy
  • Stable redox compositions and methods of use
    Patent number: 10292911
    Abstract: Described herein are compositions that include a saline solution and reactive oxygen species. Specifically, the composition may include a saline solution, reactive oxygen species, an emollient, and a pH modifier. Also provided is a gel composition that includes a rheology agent. Also provided are methods of making and using the compositions.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: May 21, 2019
    Assignee: Reoxcyn, LLC
    Inventor: Kurt Richards
  • Pharmaceutical composition of ibuprofen and tramadol for ophthalmic use
    Patent number: 10292953
    Abstract: The present invention relates to a pharmaceutical composition of ibuprofen and tramadol for ophthalmic use. Said composition is effective and safe for the treatment of ocular inflammation and/or pain associated to different diseases or pathological states which affect the eye area In particular, the ophthalmic composition of the invention is indicated, for example, for the treatment of pain and/or inflammation after eye surgery.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: May 21, 2019
    Inventors: Fernando Martinez-Alzamora, Jose Miguel Rizo Martinez, Antonia Gomez Calvo, Nuria Sanz Menendez, Angel Munoz Ruiz
  • Steroid hormone compositions in medium chain oils
    Patent number: 10286077
    Abstract: This disclosure provides a novel pharmaceutical composition capable of forming micelles upon exposure to the gastric environment. The pharmaceutical composition is suitable for delivering steroid hormones, and progesterone in particular, to a subject in need thereof.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: May 14, 2019
    Assignee: TherapeuticsMD, Inc.
    Inventors: Annette Shadiack, Peter H. R. Persicaner, Philip B. Inskeep, Thorsteinn Thorsteinsson, Frederick D. Sancilio, Jason D. Legassie